-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448

Benzinga·11/06/2026 17:51:31
Listen to the news
Truist Securities analyst Gregory Renza reiterates BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $448.